pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Wafermine
drug
save

ketamine

Phase 3updated 6mo ago
by $NRXP NRX Pharmaceuticals, Inc.
Phase 3
community read0 votes

🐶 often sniffed alongside

top 8
  • drugKETAMINE HYDROCHLORIDE59 co-mentions · 32 sources
  • drugKetalar59 co-mentions · 32 sources
  • tagApproval58 co-mentions · 29 sources
  • tagRecall10 co-mentions · 10 sources
  • tagPain4 co-mentions · 1 sources
  • drugflumazenil4 co-mentions · 4 sources
  • tagOncology2 co-mentions · 1 sources
  • tagBreast Cancer2 co-mentions · 1 sources

all catalysts(1)

phase 1 2 completion · 1
Apr 24, 2026
phase 1 2 completion
7mo ago
University of Otago — ketamine (Phase I/II Trial Completion)
ketamine
→

Trials studying ketamine

  • phase3A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depressionrecruitingn=348
  • phase3A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorderrecruitingn=258
  • phase4A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depressionrecruitingn=47
  • —Anesthetics and Analgesics in Childrenrecruitingn=500
  • phase3Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headachesrecruitingn=56
  • phase1Ketamine Biomarker Validationnot yet recruitingn=20
  • phase4A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatmentcompletedn=183
  • phase1Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participantscompletedn=22

News(10)

  • HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
    Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.
    biospace · 3d ago
  • ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veterans
    The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).
    fiercebiotech · 4d ago
  • Delix raises $100M to advance at-home psychedelic without hallucinatory effects
    The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
    biospace · 6d ago
  • Delix raises $100M to advance at-home psychedelic without hallucinogenic effects
    The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
    biospace · 6d ago
  • J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
    Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.
    fiercebiotech · 8d ago
  • STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds
    Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.
    stat · 24d ago
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    stat · 24d ago
  • STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
    A personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to a standard treatment
    stat · 24d ago
  • STAT+: Gilead to pay $45 million to settle kickback charges filed by Texas attorney general
    Gilead Sciences agreed to pay $45 million to settle allegations of paying kickbacks that improperly influenced prescriptions paid for by the Texas Medicaid program
    stat · 25d ago
  • STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
    U.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutiny
    stat · 25d ago
view all news mentions →
brand
Wafermine
generic
ketamine [INN]
indication
Bipolar Disorder (Manic Depression)
phase
phase_3
Data sources
ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?